Australia's largest stock trading and investment forum Australia's #1 stock forum

PAR

13.0%

52.0¢ paradigm biopharmaceuticals limited..

Fifty One Capital updated report, page-36

First 36 Last

Share
Profile

Follow
rusty388

502 Posts.

113

28/11/18

18:59

Post #: 36676151
Share

Originally posted by Gearitup ↑

Yes Morgans have a "reduce" today on PAR:
Paradigm BiopharmaceuticalA win already priced in
■ PAR is a clinical stage biopharmaceutical company focused on the treatment oforthopaedic and viral arthritis through its repurposed drug pentosane polysulfatesodium (iPPS).
■ The outcome of the OA trial before EOCY18 is expected to generate significantinterest as a non-opioid and non-steroid based treatment.
■ Strong SAS results to date have spurred a rally in the share price over the last 12months, and we believe high levels of trial success are already priced in.
■ We initiate coverage on PAR with a Reduce recommendation and valuation rangeof A$0.16 to A$2.10 and price target of A$0.89. We note an investment in PAR isappropriate for investors with a higher risk profile.

Valuation range reflects binary natureWe have run a number of scenarios assuming different outcomes including: low (trialfailure), current state (Ph2 pending), current state (Ph2 success), and a high case(unrisked) scenario. The valuation range between scenarios reflects the binary nature ofthe asset and consequently the large risk/reward profile it presents. Based on thesuccesses of the SAS program to date and subsequent rally in the share price, webelieve the market is already factoring in a high chance of success of the OA trial.

Investment view – taking profits ahead of binary eventWe initiate coverage on PAR with a risked valuation range of A$0.16 (Ph2 failure) toA$2.10 (unrisked commercialised). While it isn’t often investors get a significant readthroughinto the potential efficacy of a drug going through a double-blind trial, the rallyover the last 12 months has increased potential risks to the downside if success is notachieved. We ultimately view trial success as the most likely scenario based on thestrong SAS outcomes to date, although set our price target on a risk-weighted basis of38% high case and 62% low case of which the high case weight representing theaverage success rate of success in Phase 2 trials. With significant value resting onmany unknowns including size and scale of potential partnership and milestone details,we advocate investors to take profits into the recent rally and await further clarity posttop-line results before reviewing and de-risking further. Risks to the upside relate tohigher than forecast partnership deal terms. Due to the risks associated with regulatoryclearance of pharmaceutical drugs, we initiate with a Reduce recommendation andA$0.89 target price. We note this investment is appropriate for investors with a higherrisk-profile.

Expand

They are just sitting on the fence.

A valuation range from $0.16 to $2.10 - yeah thanks for that. I could make predictions like that too.

Anyone remember Peptech (Arana).... ?

PAR Price at posting: $1.16 Sentiment: Buy Disclosure: Held
2 Upvote

1 Great analysis

Reply

Top Stories

MIN

MinRes's Ellison knows he screwed up – for that reason, hunt for new Chair to be sped up

ACW

This biotech stock raised $11M in a risk-off environment. Its Alzheimer's drug could change the game

History-making uranium sample grades and an imminent drill run. Infini Resources is poised to transform in 2025

WC8

Pan Asia rebranding to 'clear confusion' after bagging $35M for Chile projects

CXM

'Taking money from the market': Garbage giant cleans up as this week's Hot Stock tip

There are more pages in this discussion • 36 more messages in this thread...

First 36 Last

Add PAR (ASX) to my watchlist

(20min delay)
Last 52.0¢		Change 0.060(13.0%)		Mkt cap ! $82.30M

Open	High	Low	Value	Volume
47.0¢	56.0¢	40.0¢	$4.475M	8.971M

Buyers (Bids)

No.	Vol.	Price($)
1	12150	49.0¢

Sellers (Offers)

Price($)	Vol.	No.
52.0¢	39994	1

View Market Depth

No.	Vol.	Price($)
2	47906	0.245
3	82048	0.240
2	32293	0.235
8	110599	0.230
7	89672	0.225

Price($)	Vol.	No.
0.250	13363	1
0.255	34148	4
0.260	6415	2
0.270	19081	2
0.275	13636	2

Last trade - 16.10pm 26/11/2024 (20 minute delay)

PAR (ASX) Chart

Fifty One Capital updated report, page-36

Top Stories

MinRes's Ellison knows he screwed up – for that reason, hunt for new Chair to be sped up

This biotech stock raised $11M in a risk-off environment. Its Alzheimer's drug could change the game

History-making uranium sample grades and an imminent drill run. Infini Resources is poised to transform in 2025

Pan Asia rebranding to 'clear confusion' after bagging $35M for Chile projects

'Taking money from the market': Garbage giant cleans up as this week's Hot Stock tip

Buyers (Bids)

Sellers (Offers)